KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• KRAS mutations are prevalent in non-small cell lung cancer (NSCLC), particularly in adenocarcinomas, smokers, and Caucasian patients.
• The prognostic and therapeutic implications of KRAS mutations in NSCLC are still under investigation.
• Directly inhibiting RAS activation has not yielded clinical benefits.

Purpose of the Study:

• To review current and emerging therapeutic strategies for KRAS-mutated NSCLC.
• To evaluate the efficacy and safety of various targeted therapies and novel approaches.
• To identify future directions in managing KRAS-mutated NSCLC.

Main Methods:

• Review of preclinical and clinical studies on KRAS-mutated NSCLC treatments.
• Analysis of data from ongoing and completed clinical trials.
• Exploration of novel therapeutic targets and drug combinations.

Main Results:

• Inhibition of mitogen-activated protein kinase (MEK) pathway targets shows promise, with combinations of MEK inhibitors and chemotherapy doubling clinical outcomes in Phase II trials.
• Dual inhibition of MEK and epidermal growth factor receptor is under early-phase investigation.
• Abemaciclib (a CDK4/6 inhibitor) demonstrated a 54% disease control rate in a Phase I trial.
• Immunotherapy is a potential future strategy due to the high mutational burden and neo-antigens in KRAS-mutated NSCLC.

Conclusions:

• Targeting downstream pathways like MEK represents a promising strategy for KRAS-mutated NSCLC.
• Combination therapies and novel agents like abemaciclib warrant further investigation.
• Immunotherapy holds significant potential for future treatment paradigms in KRAS-mutated NSCLC.